Validation of the rheumatoid arthritis diagnosis in the Swedish National patient register: a cohort study from Stockholm County

详细信息    查看全文

• 作者：Kristin Waldenlind (26) (27)
  Jonas K Eriksson (27)
  Bernhard Grewin (26)
  Johan Askling (26) (27)
  
  26. Department of Rheumatology ; Karolinska University Hospital ; Stockholm ; Sweden
  27. Clinical Epidemiology Unit ; Department of Medicine Solna ; Karolinska Institutet ; SE-171 76 ; Stockholm ; Sweden
  
• 关键词：Epidemiology ; Rheumatoid arthritis ; Clinical registers ; Validation
• 刊名：BMC Musculoskeletal Disorders
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：15
• 期：1
• 全文大小：253 KB
• 参考文献：1. Askling, J, Fored, CM, Geborek, P, Jacobsson, LT, van Vollenhoven, R, Feltelius, N, Lindblad, S, Klareskog, L (2006) Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 65: pp. 707-712 CrossRef
  2. Eriksson, JK, Neovius, M, Ernestam, S, Lindblad, S, Simard, JF, Askling, J (2013) Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res 65: pp. 870-878 CrossRef
  3. Neovius, M, Simard, J, Sundstrom, A, Jacobsson, L, Geborek, P, Saxne, T, Feltelius, N, Klareskog, L, Askling, J, Group, AS (2011) Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 70: pp. 516-519 CrossRef
  4. Neovius, M, Simard, JF, Askling, J (2011) group As: Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 70: pp. 624-629 CrossRef
  5. Neovius, M, Sundstrom, A, Simard, J, Wettermark, B, Cars, T, Feltelius, N, Askling, J, Klareskog, L, Group, AS (2011) Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 40: pp. 8-15 CrossRef
  6. Askling, J, Baecklund, E, Granath, F, Geborek, P, Fored, M, Backlin, C, Bertilsson, L, Coster, L, Jacobsson, LT, Lindblad, S, Lysholm, J, Rantap盲盲-Dahlqvist, S, Saxne, T, van Vollenhoven, R, Klareskog, L, Feltelius, N (2009) Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68: pp. 648-653 CrossRef
  7. Askling, J, Dixon, W (2008) The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 20: pp. 138-144 CrossRef
  8. Askling, J, Dixon, W (2011) Influence of biological agents on cardiovascular disease in rheumatoid arthritis. Ann Rheum Dis 70: pp. 561-562 CrossRef
  9. Askling, J, Fored, CM, Brandt, L, Baecklund, E, Bertilsson, L, Feltelius, N, Coster, L, Geborek, P, Jacobsson, LT, Lindblad, S, Lysholm, J, Rantap盲盲-Dahlqvist, S, Saxne, T, van Vollenhoven, RF, Klareskog, L (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66: pp. 1339-1344 CrossRef
  10. Askling, J, van Vollenhoven, RF, Granath, F, Raaschou, P, Fored, CM, Baecklund, E, Dackhammar, C, Feltelius, N, Coster, L, Geborek, P, Jacobsson, LT, Lindblad, S, Rantap盲盲-Dahlqvist, S, Saxne, T, Klareskog, L (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 60: pp. 3180-3189 CrossRef
  11. Raaschou, P, Simard, JF, Holmqvist, M, Askling, J, Group, AS (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346: pp. f1939 CrossRef
  12. Raaschou, P, Simard, JF, Neovius, M, Askling, J (2011) Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 63: pp. 1812-1822 CrossRef
  13. Simard, JF, Neovius, M, Askling, J, Group, AS (2012) Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 64: pp. 3502-3510 CrossRef
  14. Baecklund, E, Iliadou, A, Askling, J, Ekbom, A, Backlin, C, Granath, F, Catrina, AI, Rosenquist, R, Feltelius, N, Sundstrom, C, Klareskog, L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54: pp. 692-701 CrossRef
  15. Knight, A, Sandin, S, Askling, J (2010) Increased risk of autoimmune disease in families with Wegener's granulomatosis. J Rheumatol 37: pp. 2553-2558 CrossRef
  16. Ludvigsson, JF, Andersson, E, Ekbom, A, Feychting, M, Kim, JL, Reuterwall, C, Heurgren, M, Olausson, PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11: pp. 450 CrossRef
  Kodningskvalitet i patientregistret 鈥?Ett nytt verktyg f枚r att m盲ta kvalitet.
  17. Aletaha, D, Neogi, T, Silman, AJ, Funovits, J, Felson, DT, Bingham, CO, Birnbaum, NS, Burmester, GR, Bykerk, VP, Cohen, MD, Combe, B, Costenbader, KH, Dougados, M, Emery, P, Ferraccioli, G, Hazes, JM, Hobbs, K, Huizinga, TW, Kavanaugh, A, Kay, J, Kvien, TK, Laing, T, Mease, P, M茅nard, HA, Moreland, LW, Naden, RL, Pincus, T, Smolen, JS, Stanislawska-Biernat, E, Symmons, D (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: pp. 2569-2581 CrossRef
  18. Arnett, FC, Edworthy, SM, Bloch, DA, McShane, DJ, Fries, JF, Cooper, NS, Healey, LA, Kaplan, SR, Liang, MH, Luthra, HS, Medsger, TA, Mitchell, DM, Neustadt, DH, Pinals, RS, Schaller, JG, Sharp, JT, Wilder, RL, Hunder, GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: pp. 315-324 CrossRef
  19. Biliavska, I, Stamm, TA, Martinez-Avila, J, Huizinga, TW, Landewe, RB, Steiner, G, Aletaha, D, Smolen, JS, Machold, KP (2013) Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. Ann Rheum Dis 72: pp. 1335-1341 CrossRef
  20. Thomas, SL, Edwards, CJ, Smeeth, L, Cooper, C, Hall, AJ (2008) How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database?. Arthritis Rheum 59: pp. 1314-1321 CrossRef
  21. Widdifield, J, Bernatsky, S, Paterson, JM, Tu, K, Ng, R, Thorne, JC, Pope, JE, Bombardier, C (2013) Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists. Arthritis Care Res 65: pp. 1582-1591
  22. Widdifield, J, Bombardier, C, Bernatsky, S, Paterson, JM, Green, D, Young, J, Ivers, N, Butt, DA, Jaakkimainen, RL, Thorne, JC, Tu, K (2014) An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance. BMC Musculoskelet Disord 15: pp. 216 CrossRef
  23. Pedersen, M, Klarlund, M, Jacobsen, S, Svendsen, AJ, Frisch, M (2004) Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. Eur J Epidemiol 19: pp. 1097-1103 CrossRef
  24. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2474/15/432/prepub
  
• 刊物主题：Orthopedics; Rehabilitation; Rheumatology; Sports Medicine; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2474

文摘

Background The Swedish National Patient Register offers unique possibilities for identification of large cohorts, such as patients with rheumatoid arthritis (RA). Although the overall diagnostic validity in the register has been reported as good, the aims of this study were to a) specifically validate the RA diagnosis from contemporary outpatient specialist care in this register, and b) assess the proportion of patients identified via algorithms to define incident RA in the register who in clinical practice also have new-onset disease. Methods 211 individuals with prevalent or incident RA in the National Patient Register were included. By extracting diagnosis-related parameters from their medical records, we determined if the patient fulfilled the 2010 ACR/EULAR- and the 1987 ACR-classification criteria for RA. We also determined whether clinical diagnosis was synchronous with disease onset as defined through register-based algorithms. Results For 91% of the prevalent patients, the RA diagnosis in the National Patient Register fulfilled classification criteria or clinical diagnosis for RA. Among individuals identified with incident RA using a strict algorithm for new-onset disease, the RA diagnosis was substantiated in 91%, of whom 92% also represented new-onset disease. Conclusions The validity of the RA diagnosis in the National Patient Register was high and, by using specific algorithms, new-onset RA can be defined. These findings strengthen the notion that the National Patient Register may be used to define RA populations with high validity to allow for high-quality epidemiological studies.